Diagnosis & management of leishmania/HIV co-infection

Indian Journal of Medical Research

Volumn 121, Issue 4, 2005, Pages 407-414

  Sinha, P K ^a   Pandey, K ^a   Bhattacharya, S K ^a  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Co infection; HIV; Leishmania; Opportunistic infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; MILTEFOSINE; NELFINAVIR; PENTAMIDINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM INFECTION; CHROMATOGRAPHY; COMORBIDITY; DRUG COST; DRUG POTENTIATION; DRUG RESPONSE; FATALITY; GASTROINTESTINAL INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LEISHMANIASIS; OPPORTUNISTIC INFECTION; PARASITE TRANSMISSION; POLYMERASE CHAIN REACTION; PREVALENCE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

HIV INFECTIONS; HUMANS; LEISHMANIASIS;

EID: 18844393094     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338 : 853-60.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalionos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352 1725-30.
3. UNAIDS: AIDS Epidemic Update 2002.
4. WHO Fact Sheet No. 116, Rev. May 2000.
5. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. Br Med J 2003; 326 : 377-82.
6. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: Current status of control, diagnosis and treatment, an a proposed research and development agenda. Lancet Infect Dis 2002; 2 : 494-501.
7. Magill AJ. Epidemiology of Leishmaniasis. Dermatol Clin 1995; 13: 505-23.
8. Kostman R, Barr M, Bengtsson E, Garnham PCC, Hult G, et al. Kala-azar transferred by exchange blood transfusion in two Swedish infants. In: Proceedings of the 7th International Congress of Tropical Medicine and Malaria. Geneva: Switzerland: World Health Organization; 1963 p. 384.
9. Loke Y. Transmission of parasites across the placenta. Advances in parasitology, New York: Academic Press; 1982; 21 : p. 155.
10. Nuwayri-Salti N, Khansa H. Direct non-infect vector transmission of leishmania parasite in mice. Int J Parasitol 1985; 15 : 497.
11. Napier L, Gupta CD. Indian Kala-azar in a new borne. Indian Med Gaz 1928; 62 : 199.
12. Rosethal PJ, Chaisson RE, Hadley WK, Leech JH. Rectal leishmaniasis in a patient with acquired immuno deficiency syndrome. Am J Med 1988; 84 : 307-9.
13. Cascio A, Colomba C, Antinori S, Orobello M, Paterson D, Titone L. Paediatric Visceral leishmaniasis in Western Sisily, Italy: A retrospective analysis of 111 cases. Eur J Clin Microbiol Infect Dis 2002; 21 : 277-82.
14. Evans TG, Teixeira MJ, McAuliffe IT, Vasconcelos I, Vasconcelos AW, Sousa Ade A, et al. Epidemiology of Visceral leishmaniasis in North-East Brazil. J Infect Dis 1992; 166 : 1124-32.
15. Belazzoug S. Leishmaniasis in Mediterranean countries. Vet Parasitol 1992; 44 : 15-9.
16. Aggarwal P, Prakash Wali JP. Profile of kala-azar in north India. Asia Pacific J Public Health 1991; 5 : 90-3.
17. Pintado V, Martin Rabadan P, Rivera ML, Morino S, Bauza E. Visceral leishmaniasis in human immunodeficiency virus infected and non-HIV infected patients- A comparative study. Medicine 2001; 80 : 54-73.
18. The World Health Report, 2001, Geneva: World Health Organization; 2001.
19. Rosenthal E, Marty P., Poizot Martin I, Reynes J, Pratlong F, Lafeuillade A, et al. Visceral leishmaniasis and HIV-1 co-infection in Southern France. Trans R Soc Trop Med Hyg 1995; 89 : 159-62.
20. Heisch RB. Studies in Leishmaniasis in East Africa: The Epidemiology of an outbreak of Kala-azar in Kenya. Trans R Soc Trop Med Hyg 1954; 48 : 449-64.
21. Reiner SL, Loksley RM. The regulation of Immunity to Leishmania major. Ammu Rev Immunol 1995; 13 : 151-77.
22. Bhattacharya S, Ghosh S, Das Gupta B., Majumdar D, Roy S, Majumdar S. Chemokine induced leishmanial activity in murine macrophages via the generation of nitric oxide. J Infect Dis 2002; 185 : 1704-8.
23. Wolday D, Akuffo F, Britton S, Hathaway A, Sander B. HIV-1 inhibits leishmania induced cell proliferation, but not TNF-alpha and IL6 production. Scand J Immunol 1994; 39 : 380-6.
24. Fahey JL. Cytokines, plasma immune activation markers, a clinically relevant serrogate markers in human immunodeficiency virus infection. Clin Diag Lab Immunol 1998; 5 : 597-603.
25. Cohen OJ, Fouci AS. Host factors that effect sexual transmission of HIV. Int J Infect Dis 1998; 2 : 182-5.
26. Cacopardo BL, Nigro Preiser W, Braner J, Cinati J, Palermo F, et al. Prolonged Th2 cell activation and increased viral replication in HIV/ Leishmania co-infected patients despite treatment. Trans R Soc Trop Med Hyg 1996; 90 : 434-5.
27. Blackwell JM. Tumour necrosis factor alpha and mucocutaneous leishmaniasis. Parasitol Today 1999; 15 : 73-5.
28. Desjeux P, Meert JP, Piot B, Alwar J, Medrano FJ, Portus M, et al. Leishmania/ HIV co-infection, South Western Europe 1990-98. Document WHO/LEISH/2000. 42 Geneva: World Health Organization.
29. Rabello A, Orsini M, Disch J. Leishmania/ HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2002; 97 : 17-28.
30. Montalban C, Martinez Fernandez R, Calleza ZL, Garcia-Diaz ZE, Rubio R, Dronda F, et al. Visceral leishmaniasis (Kala-azar) as an opportunistic infection in patients infected with human immunodeficiency virus in Spain. Rev Infect Dis 1989; 11 : 655-60.
31. del Mar Sanz M, Rubio R, Casillas A, Guijarro C; Costa JR, Martinez R. de Dios Garcia J. Visceral leishmaniasis in HIV infected patients. AIDS 1991; 5 : 1272-4.
32. Alvar J, Canavate C, Gutierrez-Solar B, Jimen EZM, Laguna F, Lopez-Velez R, et al. Leishmania and human immunodeficiency virus co-infection: The first 10 years. Clin Microbiol Rev 1997; 10 : 298-319.
33. Evans TG. Leishmaniasis. Infect Dis Clin North Am 1993; 7 : 527-46.
34. Montalban C, Calleja JL, Erice A, Laguna F, Clotet B, Podzamczer D, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus- Co-operative group for the study of Leishmaniasis in AIDS. J Infect 1990; 21 : 261-70.
35. Alvar J, Gutierrez-Solar B, Molina R, et al. Prevalence of leishmania infection among AIDS patients. Lancet 1992; 339 : 264-65.
36. Miralles P, Moreno S, Perez-Tascon M, Cosin J, Diaz MD, Bouza E. Fever of uncertain origin in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20 : 872-5.
37. Janoff EN, Smith PD. Perspectives on gastro-intestinal infections in AIDS. Gastrointerol Clin North Am 1988; 17 : 451-63.
38. Malebranche R, Arnoux E, Guerin JM, Pierre GD, Laroche SE, Pean-Guichard C, et al. Acquired immunodeficiency syndrome with severe gastrointestinal manifestations in Haiti. Lancet 1983; 2 : 873-8.
39. Laguna F, Garcia-Samaniego J, Sorianao V, Valencia E, Redondo C, Alonso MJ, et al. Gastro-intestinal leishmaniasis in human immunodeficiency virus infected patients: Report of 5 cases and review. Clin Infect Dis 1994; 19 : 48-53.
40. Muigai R, Gatei D, Shaunak S, et al. Jejunal function and pathology in visceral leishmaniasis. Lancet 1983; 27 : 476-9.
41. Villanueva JL, Torre-Cisneros J, Jurado F, et al. Leishmania esophagitis in an AIDS patient: an unusual form of visceral leishmaniasis. Am J Gastroenterol 1994; 89 : 273-5.
42. Perrin C, Taillan B, Hofman P, Mondain V, Lefichoux Y, Michiels JF. Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatopathol 1995; 17 : 145-50.
43. Romeu J, Milla F, Batlle M, Sirera G, Ferrendiz C, Carreres A, Condom MJ, Clotet B. Visceral leishmaniasis involving lungs and a cutaneous Kaposi's sarcoma lesions. AIDS 1991; 5 : 1272.
44. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/TNF in patients with AIDS. Am J Med 1988; 85 : 289-91.
45. Duarte MIS, da Matta VLR, Corbett CEP, Laurenti MD, Chebabo R, Goto H. Interstitial pneumonitis in human visceral leishmaniasis. Trans R Soc Trop Med Hyg 1989; 83 : 73-6.
46. Clevenbergh P, Okome MN, Benoit S, et al. Acute renal failure as initial presentation of visceral leishmaniasis in an HIV I infected patient. Scand J Infect Dis 2002; 100 : 71-4.
47. Pandey K, Sinha PK, Ravidas VNR, Kumar N, Verma N, Lal CS, et al. Nexus of infection with human immunodeficiency virus, pulmonary tuberculosis and visceral leishmaniasis: A case report from Bihar, India. Am J Trop Med Hyg 2005; 72 : 30-2.
48. Pandey K, Sinha PK, Ravidas VNR, Sur D, Kumar Nawin, Bhattacharya SK. Neurocysticercosis in a patient with visceral leishmaniasis co-infected with HIV- A case report. Infect Dis Clin Practice (in press).
49. Berenguer J, Moreno S, Cercenado E, Bernaldo de Quiros JC, Garcia de la, Fuente A, et al. Visceral leishmaniasis in patients infected with human deficiency virus (HIV). Ann Intern Med 1989; 111 : 129-32.
50. Greder A, Malet M, Gautier P, et al. Pleurisy revealing leishmaniasis in acquired immunodeficiency syndrome. Presse Med 1989; 18 : 1390-1.
51. Gonzalez-Anglada MI, Pena JM, Barbado FJ, Gonzalez JJ, Redondo C, Galera C, et al. Two cases of laryngeal leishmaniasis in patients infected with HIV. Eur J Clin Microbiol Infect Dis 1994; 13 : 509-11.
52. Mondain-Miton V, Toussaint-Gari M, Hofman P, Marty P, Carles M, Desalvoldor F, et al. Atypical leishmaniasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 : 663-5.
53. Mofredj A, Guerin MJ, Leibinger F, Masmoudi R. Visceral leishmaniasis with pericarditis in an HIV infected patient. Scand J Infect Dis 2002; 34 : 151-3.
54. Vazquez-Pineiro T, Fernandez-Alvarez JM, Gonzalo Lafuente JC, Cano J, Gimeno M, Berenger J, et al. Visceral leishmaniasis: a lingual presentation in a patient with HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86 : 179-82.
55. Miralles ES, Nunez M, Hilara Y, Harto A, Moreno R, Ledo A. Mucocutaneous leishmaniasis and HIV. Dermatology 1994; 189 : 275-7.
56. Gari-Toussaint M, Lelievre A, Marty P, Le Fichoux Y. Contribution of serological tests to the diagnosis of visceral leishmaniasis in patients infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 1994; 88 : 301-2.
57. Mary C, Lamouroux D, Dunan S, Quilici M. Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg 1992; 47 : 764-71.
58. Santos-Gomes G, Gomes-Perreira S, Campino L, Araujo MD, Abranches P. Performance of immunoblotting in diagnosis of visceral leishmaniasis in human immunodeficiency virus-Leishmania sp.- co-infected patients. J Clin Microbiol 2000; 38 : 175-8.
59. Martinez P, de la Vega E, Laguna F, Soriano V, Puente S, Moreno V, et al. Diagnosis of visceral leishmaniasis in HIV infected patients using peripheral blood smears. AIDS 1993; 7 : 227-30.
60. Medrano FJ, Jimenez-Mejias E, Calderon E, Regordan C, Leal M. An easy and quick method for visceral leishmaniasis in HIV-1-infected individuals. AIDS 1993; 7 : 1399.
61. Lopez-Velez R, Laguna F, Alvar J, Perez-Molina JA, Molina R, Martinez P, et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus infected patients. J Clin Microbiol 1995; 33 : 937-9.
62. Sundar S, Reed S, Singh V, Kumar P, Murray H. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998; 351 : 563-5.
63. Lopez M, Inga R, Cangalaya M, Echevarria J, Llanos-Cuentas A, Orrego C, et al. Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work. Am J Trop Med Hyg 1993; 49 : 348-56.
64. de Brujin MH, Labrada LA, Smyth AJ, Santrich C, Barker DC. A comparative study of diagnosis by the polymerase chin reaction and by current clinical methods using biopsies from Colombian patients with suspected lesihmaniasis. Trop Med Parasitol 1993; 44 : 201-7.
65. Cruz I, Canavate C, Rubio JM, et al. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 2002; 96 (Suppl 1) : S185-9.
66. Fisa R, Riera C, Ribera E, Gallego M, Portus M. A nested polymerase chain reaction for diagnosis and follow up of human visceral leishmaniasis patients using blood samples. Trans R Soc Trop Med Hyg 2002; 96 (Suppl 1) : S191-4.
67. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6 : 849-54.
68. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent: HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95 : 668-72.
69. Thakur CP, Sinha GP, Pandey AK. Kumar N, Kumar P, Hassan SM, et. al. Do the diminishing efficacy and increasing toxicity of sodium sitbogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as first line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92 : 561-9.
70. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral Leishmaniasis in Human Immunodeficiency Virus (HIV) - Infected and Non-HIV-infected patients: A comparative study. Medicine 2001; 80 : 54-73.
71. Laguna F, Lopez-Velez R, Pulido F. Treatment of Visceral Leishmanisis in HIV infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13 : 1063-9.
72. Autran B, Crxelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T-cell Homeostasis and function in advanced HIV disease. Science. 1997; 277 : 112-6.
73. McBride M, Linney M, Calydon EJ, Weber J. Visceral leishmaniasis following treatment with liposomal amphotericin B. Clin Infect Dis 1994; 19 : 362.
74. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341 : 1795-800.
75. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347 : 1739-46.
76. Thakur CP, Sinha PK, Singh RK, Hassan SM, Narain S. Miltefosine in case of visceral leishmaniasis with HIV co-infection and rising incidence of this disease in India. Trans R Soc Trop Med Hyg 2000; 94 : 696-7.
77. Matherson S, Cabie A, Parquin F, Mayaud C, Roux P, Antoine M, et al. Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis. AIDS 1992; 6 : 238-40.
78. Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampacin and the combination of indinavir and low dose ritonavir in HIV infected patients. Clin Infect Dis 2004; 38 : 426-9.
79. Van Oosterhout JJ, Boeree MJ, Burger DM, de Lange WC, Van Crevel R, Koopmans PP. Tuberculosis and HIV co-infection in three patients: the possibilities for simultaneous treatment. Ned Tijdschr Geneeskd (Article in Dutch). 2003; 147 : 369-72.
80. Spradling P, Drociuk D, McLaughlin S, Lee LM, Peloquin CA, Gallicano K, Pozsik C, Onorato I, Castro KG, Ridzon R. Drug-drug interactions in inmates treated for human immunodeficiency virus and mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infect Dis 2002; 35 : 1106-12.